Autoimmune Basis for Postural Tachycardia Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05043051 |
Recruitment Status :
Recruiting
First Posted : September 13, 2021
Last Update Posted : March 7, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postural Tachycardia Syndrome | Device: Vagal stimulation Device: Sham stimulation | Not Applicable |
The present study is designed to test the hypothesis that muscarinic autoantibody-mediated parasympathetic dysfunction contributes to the pathogenesis of POTS, and that parasympathetic (vagal) stimulation improves POTS symptoms, autoimmunity and inflammation.
Define and determine the prevalence, burden, and clinical significance of muscarinic autoantibodies in a well-phenotyped cohort of POTS patients with and without gastroparesis and a matched cohort of healthy control subjects.
Evaluate the impact of vagal stimulation on antibody suppression, inflammatory inhibition, and symptom improvement in POTS patients. Non-invasive transcutaneous stimulation of the auricular branch of the vagus nerve (tragus stimulation) will be used to increase parasympathetic activity.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Other |
Official Title: | Autoimmune Basis for Postural Tachycardia Syndrome |
Actual Study Start Date : | January 14, 2022 |
Estimated Primary Completion Date : | February 28, 2025 |
Estimated Study Completion Date : | July 31, 2025 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Vagal stimulation
Vagal stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the tragus for 2 months.
|
Device: Vagal stimulation
Vagal stimulation
Other Name: Transcutaneous electrical nerve stimulation |
Sham Comparator: Sham stimulation
Sham stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the earlobe for 2 months.
|
Device: Sham stimulation
Sham vagal stimulation
Other Name: Transcutaneous electrical nerve stimulation |
- Heart rate variability [ Time Frame: 5 minute ]Average of heart rate variability during the posture test
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 18-80 years old, female or male
- Either healthy control or individual with postural tachycardia syndrome (POTS) defined as heart rate increase >30 bpm from supine within 10 min of standing, in the absence of orthostatic hypotension (>20/10 mmHg fall in blood pressure), with chronic symptoms (>6 months), and in the absence of other acute cause of orthostatic tachycardia
- Able and willing to provide informed consent
- Understand and be able to comply with the study procedures and restrictions
Exclusion Criteria:
- Hypertension (>150 mmHg systolic and >100 mmHg diastolic) based on history or findings at screening
- Orthostatic hypotension (consistent drop in blood pressure >20/10 mmHg with 10 min of standing)
- Cardiovascular disease, such as myocardial infarction within 6 months
- History or presence of significant immunological or hematological disorders
- History of vagotomy
- Currently pregnant women or women planning on becoming pregnant ≤ 3 months
- Inability to comply with the protocol
- Patients with active implants (such as a cardiac pacemaker, or a cochlear implant)
Healthy control subjects will be healthy, non-smoking and on no chronic medications at the time of the study. Healthy control subjects will be group-matched to the POTS patients for age and gender.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05043051
Contact: Xichun Yu | 405-271-5896 ext 47779 | xichun-yu@ouhsc.edu | |
Contact: Brittany Karfonta | 405-271-3480 ext 34889 | Brittany-Karfonta@ouhsc.edu |
United States, Oklahoma | |
Oklahoma Clinical and Translational Science Institute | Recruiting |
Oklahoma City, Oklahoma, United States, 73104 | |
Contact: Brittany Karfonta 405-271-3480 OSCTR@ouhsc.edu | |
Principal Investigator: Stavros Stavrakis, MD |
Study Director: | Stavros Stavrakis, MD | University of Oklahoma |
Responsible Party: | University of Oklahoma |
ClinicalTrials.gov Identifier: | NCT05043051 |
Other Study ID Numbers: |
13705 2R01HL128393-04 ( U.S. NIH Grant/Contract ) |
First Posted: | September 13, 2021 Key Record Dates |
Last Update Posted: | March 7, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
POTS Vagal Stimulation Autoantibody |
Postural Orthostatic Tachycardia Syndrome Tachycardia Syndrome Disease Pathologic Processes Arrhythmias, Cardiac Heart Diseases |
Cardiovascular Diseases Cardiac Conduction System Disease Orthostatic Intolerance Primary Dysautonomias Autonomic Nervous System Diseases Nervous System Diseases |